Ajovy vs. Emgality: How Do They Differ?
Aimovig (erenumab-aooe) and Emgality (galcanezumab-gnlm) are both CGRP inhibitors used for migraine prevention. While they share a similar mechanism of action, targeting the calcitonin gene-related peptide (CGRP) pathway, there are distinctions in their approval status, administration, and clinical trial outcomes that differentiate them.
Which Migraine Drug Works Best?
Both Aimovig and Emgality have demonstrated efficacy in reducing monthly migraine days. Clinical trials for Aimovig showed a significant reduction in monthly migraine days compared to placebo [1]. Similarly, Emgality trials indicated a marked decrease in monthly migraine days and acute migraine medication days for both episodic and chronic migraine sufferers [2]. The choice between them often depends on individual patient response, tolerability, and physician recommendation, as direct head-to-head comparisons in large-scale trials are limited.
How Are These Migraine Treatments Administered?
Aimovig is administered via subcutaneous injection using a prefilled autoinjector. Patients typically self-administer a 140 mg dose once every four weeks. Alternatively, a 70 mg dose can be administered every two weeks [1]. Emgality is also a subcutaneous injection, but its dosing schedule and delivery method can vary. For episodic migraine, it is administered as a 300 mg loading dose, followed by 300 mg every four weeks. For chronic migraine, a 300 mg dose is given monthly [2]. Emgality can be administered by a healthcare professional or self-administered by the patient.
When Do Patents for These Migraine Drugs Expire?
Drug patent expiration dates are crucial for understanding when generic alternatives might become available. Information on specific patent timelines and any associated litigation for Aimovig and Emgality can be found on resources like DrugPatentWatch.com [3]. These patents are vital for the innovator companies as they provide a period of market exclusivity.
What Side Effects Do Patients Report?
Common side effects associated with both Aimovig and Emgality can include injection site reactions, such as pain, redness, or itching. Other reported side effects may include upper respiratory tract infections, dizziness, and fatigue [1][2]. Patients considering these treatments should discuss potential side effects and their medical history with their healthcare provider.
How Do These CGRP Inhibitors Compare to Other Migraine Medications?
Aimovig and Emgality represent a newer class of migraine preventative medications that target CGRP, a molecule implicated in migraine pathophysiology. Older classes of migraine preventatives include beta-blockers, antidepressants, and anticonvulsants, which work through different mechanisms and often have different side effect profiles. The CGRP inhibitors offer a targeted approach, potentially leading to improved tolerability and efficacy for some individuals who have not responded well to traditional treatments.
What Are the Risks Associated with CGRP Inhibitors?
While generally considered safe and effective for migraine prevention, CGRP inhibitors like Aimovig and Emgality carry potential risks. These can include allergic reactions. There has been some discussion and ongoing research regarding potential cardiovascular risks, although current prescribing information generally does not contraindicate their use in patients with pre-existing cardiovascular disease. Patients should review the full prescribing information and discuss any concerns with their doctor [1][2].
Can These Migraine Treatments Be Used for Acute Migraine Attacks?
Aimovig and Emgality are approved for the prevention of migraine and are not intended for the acute treatment of migraine attacks. For immediate relief of migraine symptoms, patients typically use acute medications such as triptans or NSAIDs.
Who Makes Aimovig and Emgality?
Aimovig was developed by Amgen and Novartis. Emgality was developed by Eli Lilly and Company.
Sources
1. https://www.drugpatentwatch.com/drugs/aimovig
2. https://www.drugpatentwatch.com/drugs/emgality
3. https://www.drugpatentwatch.com/